Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome

Direct Angiotensin II Type 2 Receptor Stimulation in N ω -Nitro- l -Arginine-Methyl Ester–Induced Hypertension

(2012) Ludovit Paulis et al.   HYPERTENSION

Novel therapeutic targets for the treatment of heart failure

(2011) Juan Tamargo et al.   NATURE REVIEWS DRUG DISCOVERY

CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function

(2010) Vedat Tiyerili et al.   BASIC RESEARCH IN CARDIOLOGY

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

(2010) Joseph Tam et al.   JOURNAL OF CLINICAL INVESTIGATION

Transforming growth factor (TGF)-β signaling in cardiac remodeling

(2010) Marcin Dobaczewski et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction

(2009) Shiang Y. Lim et al.   BASIC RESEARCH IN CARDIOLOGY

Cleaved high molecular weight kininogen, a novel factor in the regulation of matrix metalloproteinases in vascular smooth muscle cells

(2009) Uwe Vosgerau et al.   BIOCHEMICAL PHARMACOLOGY

The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy

(2009) Nicole Defer et al.   FASEB JOURNAL

Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure

(2009) Florian Weis et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Angiotensin II Type 2 Receptor Stimulation

(2008) Elena Kaschina et al.   CIRCULATION

Modulation of the Endocannabinoid System in Cardiovascular Disease

(2008) Pál Pacher et al.   HYPERTENSION